Home  >  Research  >  Labs  >  Cancer Program  >  MELANOMA DISCOVERY

RESEARCH OVERVIEW

Melanoma is a disease that develops when pigment cells called melanocytes contract changes (mutations) in the genetic material (DNA). These changes result in uncontrolled growth and the formation of a melanoma tumour. A leading cause of mutations in skin melanocytes is UV light from sun exposure. Since fair skin individuals do not have a natural protection against UV damage, Australia and New Zealand has the most cases of skin melanoma per capita in the world.

If melanoma is excised early the prognosis can be excellent, but if some of the melanoma cells have spread (metastasised) to distant sites in the body then the prognosis has historically been dismal. However, research into genetics and immunology has brought forward two types of therapy, targeted therapy and immunotherapy, which in some patients can be curative. Unfortunately, not all patients respond or have the correct mutations to be treated with these new therapies. One group of patients which are particularly bad off are those where the melanoma arises in the eye, as opposed to the skin where most melanoma develops from.

The Melanoma Discovery team aims to identify new treatment options for melanoma patients based on translational and clinical research, with a special interest in eye (or uveal) melanoma. Focus lies on furthering the understanding of the genetics of melanoma and creating humanised animal models of metastatic skin and uveal melanoma (PDX) for use in translational research. A major interest is also to see the discoveries translated into investigator-initiated clinical trials.

The Melanoma Discovery team is also involved with research into pancreatic cancer. The team makes patient-derived mouse models (PDX, mouse avatars) from surgical biopsies of patients with pancreatic cancer. A reason why this work is relevant to the Perkins activities is that pancreatic cancer metastasises to the liver, just like uveal melanoma. The aim is to understand why liver metastases of uveal melanoma and pancreatic cancer are so hard to treat, even with immunotherapy.

In 2021, the Melanoma Discovery team co-founded the Western Australian Melanoma Initiative. Learn about WAMI here.

Professor Elin Gray

Professor Elin Gray

Chair Melanoma Discovery

Read more

LATEST NEWS

Medibank Grant for Aboriginal Cancer Journey Coordinator

Associate Professor Andrew Redfern, Group Leader Translational Oncology lab from the Harry Perkins Institute of Medical Research and Consultant Medical Oncologist at Fiona Stanley Hospital; Ms Leanne Pilkington, Honorary Senior Cancer Research Associate at the Perkins; and Dr Katie Meehan, Senior Research Officer at the Perkins and Adjunct Senior Lecturer…

Read More

UWA Research Awards – Special Commendation awarded to Perkins Researcher

Professor Pilar Blancafort, Group Leader of the Cancer Epigenetics laboratory and Head of the Cancer Program at the Harry Perkins Institute of Medical Research and The University of Western Australia’s Centre for Medical Research received a Special Commendation from the Judging Panel at the 2026 UWA Vice-Chancellor's Senior Research Award,…

Read More

Perkins researchers win big at the WA Innovators of the Year Awards

Prof Shirley Jansen (left), A/Prof Juliana Hamzah (middle), Atherid Therapeutics CEO Meghan Thomas (right) Last night Associate Professor Juliana Hamzah, Professor Shirley Jansen AM and Atherid Therapeutics were the recipients of the Community Benefit and Wellbeing Award at the Western Australia's Innovators of the Year event. Co-founders of CAD SPECTRAL…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS